Clinical trials in Chaidari – page 59

1 008 clinical trials in Chaidari, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GreeceΚλινικεσΔοκιμεσ.gr

Chaidari at a glance

1 008

clinical trials

Research sites1

Quick filters

1 008 trials in Chaidari

Open in trial search

Bladder transitional cell carcinoma+2

Not recruiting

Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

Registered drugNo placebo

Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:AstraZeneca AB

Contact Research Centre

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo

Greece

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:Day One Biopharmaceuticals Inc.

Contact Research Centre

Hodgkin's disease

Not recruiting

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo

Greece

Participants:18–64 years
Substances:Brentuximab Vedotin
Sponsor:Fundacion Geltamo

Contact Research Centre

Acute myeloid leukaemia (in remission)

Not recruiting

Study of Galinpepimut-S compared to standard therapy for patients with acute myeloid leukemia who achieved complete remission after second-line treatment

Registered drugNo placebo

Study of Galinpepimut-S compared to standard therapy for patients with acute myeloid leukemia who achieved complete remission after second-line treatment

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Sellas Life Sciences Group Inc.

Contact Research Centre

Duchenne muscular dystrophy

Not recruiting

Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

InvestigationalNo placebo

Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

InvestigationalNo placebo

Greece

Participants:0–17 years
Substances:Eteplirsen
Sponsor:Sarepta Therapeutics Inc.

Contact Research Centre

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational

Greece

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lutikizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Head and neck cancer

Not recruiting

Study of NBTXR3 and Cetuximab with Radiotherapy for Elderly Patients with Advanced Head and Neck Cancer Not Eligible for Platinum Chemotherapy

Registered drugNo placebo

Study of NBTXR3 and Cetuximab with Radiotherapy for Elderly Patients with Advanced Head and Neck Cancer Not Eligible for Platinum Chemotherapy

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Nanobiotix

Contact Research Centre

Systemic candida

Not recruiting

Study of Recombinant Interferon-Gamma 1b Combined with Standard Treatment for Patients with Candidemia: Safety and Effectiveness Evaluation

Registered drugNo placebo

Study of Recombinant Interferon-Gamma 1b Combined with Standard Treatment for Patients with Candidemia: Safety and Effectiveness Evaluation

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Sponsor:Stichting Radboud University Medical Center

Contact Research Centre

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Buloxibutid
Sponsor:Vicore Pharma AB

Contact Research Centre

Malignant peritoneal neoplasm+2

Not recruiting

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:pharmaand GmbH

Contact Research Centre

Dermatomyositis

Not recruiting

Study on the Safety and Efficacy of Empasiprubart for Adults with Dermatomyositis

Investigational

Study on the Safety and Efficacy of Empasiprubart for Adults with Dermatomyositis

Investigational

Greece

Participants:18–64 years · 65+ years
Sponsor:Argenx

Contact Research Centre

Major depression+1

Not recruiting

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational

Greece

Participants:18–64 years
Substances:Aticaprant
Sponsor:Janssen Cilag International

Contact Research Centre

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Chaidari

What the registry says about research in the country

01 Head and Neck Cancer Research

Innovative clinical research focusing on squamous cell carcinoma of the head and neck, exploring combination therapy approaches that integrate immunotherapy with traditional treatments.

Immunotherapy Integration
Combination Treatment Strategies
Post-Surgery Care

The study evaluates the effectiveness of combining nivolumab with standard cisplatin-radiotherapy, aiming to improve disease-free survival rates in patients with resected head and neck cancer.

Back to Greece All countries